Clay Siegall, Morphimmune CEO
Updated: Ex-Seagen chief Clay Siegall emerges as CEO of private biotech
Clay Siegall will be back in the CEO seat, taking the helm of a private startup working on targeted cancer therapies.
It’s been almost a year since Siegall resigned from Seagen, the biotech he co-founded and led for more than 20 years, in the wake of domestic violence allegations by his then-wife. His eventual successor, David Epstein, sold the company to Pfizer in a $43 billion deal unveiled last week.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters